Investors are often reluctant to fund stem cell startups and may not be aware of the differences between embryonic and adult stem cells and their potential uses as therapies, said Hadar Ron of Israel HealthCare Ventures and Yael Margolin, Gamida Cell's CEO. In this interview, Margolin said she believes that the Obama administration's decision to ease funding restrictions on embryonic stem cell research will renew investors' interest in the field.

Related Summaries